Compare Amphastar Pharmaceuticals Inc (AMPH) vs Tilray Brands Inc (TLRY) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

TLRY trades at $4.42, up 0.68% on the day, with a bearish technical outlook and mixed fundamentals. The stock shows low valuation ratios (P/S 0.55, P/B 0.35) but deep losses (net margin -156.67%) and negative cash flow from operations. Recent news highlights expansion in medical cannabis and new product launches, yet earnings misses and high debt-to-asset ratios signal ongoing challenges.

Outlook remains uncertain with profitability elusive; growth via acquisitions adds scale but not earnings. Analyst consensus is cautious (25% buy, 65% hold), reflecting skepticism about near-term turnaround. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles in the cannabis sector.